Serous cystic neoplasm (SCN) of the pancreas is considered a benign tumor with almost no malignant potential. Most surgeons agree that asymptomatic SCN requires only regular observation. However, several complexities and interference with organ preservation during the operation, may develop when a huge symptomatic tumor is treated with surgery. So, the purpose of this study is to develop a potential management plan based on a literature review and by describing three recent cases of SCN of the pancreas. We suggest that SCNs be responded to with a timely and appropriate surgical intervention -before they require clinical attention.
Introduction
Ten to 20 percent of pancreatic cysts are neoplastic cysts, and malignant cystic neoplasms account for about 1% of malignant pancreatic tumors.
1,2 Unlike mucinous cystic neoplasm or intraductal papillary mucinous neoplasm of the pancreas, pancreatic serous cystic neoplasm is considered a benign tumor with almost no malignant potential. Only expectant management with serial follow-up need be provided, and surgery is not recommended in the absence of symptoms. Since, George et al. 3 reported the first case of serous cystadenocarcinoma in 1989, only about 25 cases have been reported around the world. 4 With the development of better socioeconomic conditions and of increasing concern for personal health, asymptomatic benign or borderline malignant cystic neoplasms of the pancreas are increasingly detected. 
Case Reports
Case 1 was a female patient admitted to our hospital due to dyspnea and a palpable mass. An abdominal CT scan showed a huge pancreatic mass compressing adjacent vascular structures and intraabdominal organs (Fig. 1A ).
She underwent spleen-preserving subtotal distal pancreatec- tomy with segmental resection of whole splenic vessels.
The tumor was reported as a serous cystadenoma ( In case 3, an incidental pancreatic tumor was found during evaluation of a woman's renal cyst (Fig. 3A ). There were no symptoms related to the pathology of the pancreatic tail. After fully understanding the natural course of serous cystic neoplasm, she agreed to surgical extirpation. Robotic spleen-preserving distal pancreatectomy conserving both splenic vessels was performed (Fig. 3B) .
The pancreatic tumor was reported as a serous cystadenoma (Fig. 3C) . All cases are summarized in Table 1 .
Discussion
Most pancreatic serous cyst neoplasms are rare and asymptomatic, with a benign nature. However, the prevalence of cancer among serous cystic neoplasms is known to be about 3%. 9 According to a recent literature review of serous cystadenocarcinoma, 4 the median age of patients is 68 years old (range, 52∼85 years), and the median tumor size is 10 cm (range, 2.5∼19 cm). This suggests that serous cystic neoplasm might eventually progress to large malignant tumors in the elderly when left without appropriate treatment. In addition, Tseng et al. 10 observed that serous cystic neoplasms smaller than 4 cm at presentation grow slowly (only about 0.12 cm/year), whereas those larger than 4 cm at presentation grow much faster (1.98 cm/year).
They also reported that larger tumors were more likely to develop symptoms later, suggesting that the tumor biology may be different according to tumor size, and that a pancreatic serous cystic neoplasm aggressively transforms as it grows. In recent clinical practice, the strategy for asymptomatic small serous cystic neoplasm, which used to be a conditional observation of a periodic axial image study, needs to be reevaluated. In the past, higher morbidity and potential mortality following pancreatectomy was thought to be a great obstacle in applying a surgical approach to asymptomatic serous cystic neoplasms. However, recent advances in surgical techniques, experiences, and preoperative management have reduced operative morbidity and mortality to generally acceptable ranges. 11 In particular, minimally invasive (laparoscopic and robotic) pancreatectomy can be safely performed these days. 12, 13 Long-term survival following successful pancreatectomy is highly expected in patients with benign and borderline malignant tumors. So, quality of life needs to be considered in choosing among surgical options. (Fig. 2) .
In summary, serous cystic neoplasm of the pancreas is rare but seems to be increasing due to easy access to medical care and improvements in pancreatic imaging.
Based on a literature review and the cases presented here, the natural course of serous cystic neoplasm appears to be related to tumor size, symptoms and malignancy. Thus, we suggest timely and appropriate surgical intervention for SCNs before they require clinical attention.
